

### **NCCN Continuing Education Disclosure Policy**

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose **ALL** financial relationships they have had in the past **24 months** with ineligible companies. The ACCME *Standards for Integrity and Independence* require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

### **Definitions**

**Ineligible Company:** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

**Relevant Financial Relationships:** Financial relationships of any dollar amount occurring within the past **24 months** are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of **ALL** financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

### **Faculty Disclaimers**

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.



**Faculty Disclosures**

***Congress Planning Committee***

The faculty listed below have **no relevant** financial relationship(s) with ineligible companies to disclose.

**Brenda K. Shelton, DNP, RN, CCRN, AOCN, NPD-BC\***

The faculty listed below have the following **relevant** financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

**Gabriela S. Hobbs, MD**

AbbVie, Inc.: Scientific Advisor  
Agiros, Inc.: Scientific Advisor  
Bayer HealthCare: Grant/Research Support  
Blueprint Medicines: Scientific Advisor  
Bristol-Myers Squibb Company: Scientific Advisor  
Celgene Corporation: Scientific Advisor  
Incyte Corporation: Grant/Research Support; Scientific Advisor  
Jazz Pharmaceuticals Inc.: Scientific Advisor  
Merck & Co., Inc.: Grant/Research Support  
Novartis Pharmaceuticals Corporation: Scientific Advisor  
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor

**Shaji K. Kumar, MD\***

AbbVie, Inc.: Grant/Research Support; Scientific Advisor  
Amgen Inc.: Grant/Research Support; Scientific Advisor  
BeiGene: Honoraria  
Bristol-Myers Squibb Company: Grant/Research Support; Scientific Advisor  
GlaxoSmithKline: Grant/Research Support; Scientific Advisor  
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor  
Karyopharm Therapeutics: Grant/Research Support; Scientific Advisor  
Loxo Oncology, Inc.: Scientific Advisor  
Regeneron Pharmaceuticals, Inc.: Grant/Research Support; Scientific Advisor  
Roche Laboratories, Inc.: Grant/Research Support; Scientific Advisor  
sanofi-aventis U.S.: Grant/Research Support; Scientific Advisor  
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support; Scientific Advisor

**Bernard Marini, PharmD, BCOP\***

Servier Laboratories: Consulting Fee

**Andrew D. Zelenetz, MD, PhD\***

AbbVie, Inc.: Consulting Fee  
Adaptive Biotech: Consulting Fee  
Amgen Inc.: Consulting Fee  
AstraZeneca Pharmaceuticals LP: Consulting Fee  
BeiGene: Consulting Fee; Grant/Research Support  
BMS/Celgene/Juno: Consulting Fee; Scientific Advisor  
Celgene Corporation: Consulting Fee  
Genentech, Inc.: Consulting Fee; Grant/Research Support  
Gilead Sciences, Inc./Kite Pharma: Consulting Fee  
Janssen Pharmaceutica Products, LP: Consulting Fee  
MEI Pharma Inc.: Consulting Fee; Grant/Research Support  
MorphoSys AG: Consulting Fee  
Novartis Pharmaceuticals Corporation: Consulting Fee  
Roche Laboratories, Inc.: Consulting Fee; Grant/Research Support

\*Presenting Faculty

*This list includes disclosures submitted to NCCN as of October 7, 2022.*



**Faculty Disclosures (continued)**

***Presenting Faculty***

The faculty listed below have **no relevant** financial relationship(s) with ineligible companies to disclose.

**Meredith G. Beaton, AG-ACNP**  
**Jason Bergsbaken, PharmD, MBA, BCOP**  
**Patrick W. Burke, MD**  
**Ryan J. Mattison, MD**  
**Jennifer L. Saullo, MD, PharmD**

The faculty listed below have the following **relevant** financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

**Jeremy S. Abramson, MD, MMSc**  
AstraZeneca Pharmaceuticals LP: Honoraria  
BeiGene: Consulting Fee; Honoraria  
bluebird bio, Inc.: Consulting Fee  
Bristol-Myers Squibb Company: Consulting Fee; Grant/Research Support; Honoraria  
Caribou Biosciences, Inc.: Consulting Fee  
Eli Lilly and Company: Consulting Fee  
Epizyme: Consulting Fee  
Genentech, Inc.: Consulting Fee  
Genmab A/S: Honoraria  
Incyte Corporation: Honoraria  
Janssen Pharmaceutica Products, LP: Consulting Fee  
Kite Pharma: Consulting Fee  
Kymera Therapeutics: Consulting Fee  
MorphoSys AG: Consulting Fee  
Mustang Bio: Consulting Fee  
Ono Pharmaceutical Co., Ltd.: Consulting Fee  
Regeneron Pharmaceuticals, Inc.: Honoraria  
Seattle Genetics, Inc.: Grant/Research Support  
Takeda Pharmaceuticals North America, Inc.: Consulting Fee

**Muhamed Baljevic, MD**  
BMS/Celgene: Scientific Advisor  
Cardinal Health Specialty Solutions: Honoraria  
CurioScience: Honoraria  
Janssen Research & Development, LLC: Scientific Advisor  
Karyopharm Therapeutics: Honoraria; Scientific Advisor  
Oncopeptides: Scientific Advisor  
Sanofi-Genzyme: Scientific Advisor



**Faculty Disclosures (continued)**

***Presenting Faculty***

The faculty listed below have the following **relevant** financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

**Uma M. Borate, MD, MSc**

AbbVie, Inc.: Grant/Research Support; Scientific Advisor  
Agiros, Inc.: Scientific Advisor  
Astellas Pharma US, Inc.: Scientific Advisor  
Blueprint Medicines: Scientific Advisor  
Genentech, Inc.: Scientific Advisor  
Incyte Corporation: Grant/Research Support  
Jazz Pharmaceuticals Inc.: Grant/Research Support  
Kura Oncology, Inc.: Scientific Advisor  
Novartis Pharmaceuticals Corporation: Scientific Advisor  
Pfizer Inc.: Grant/Research Support  
RUNX1 Foundation: Honoraria  
Servier Laboratories: Scientific Advisor  
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor

**Christopher R. D'Angelo, MD**

AbbVie, Inc.: Consulting Fee  
Bristol-Myers Squibb Company: Grant/Research Support  
Fate Therapeutics: Grant/Research Support  
TG Therapeutics, Inc.: Consulting Fee

**Aaron T. Gerds, MS, MS**

AbbVie, Inc.: Consulting Fee  
Bristol-Myers Squibb Company: Consulting Fee  
CTI BioPharma Corp.: Consulting Fee  
Imago Biosciences: Consulting Fee  
Kartos Therapeutics, Inc.: Consulting Fee  
MorphoSys AG: Consulting Fee  
Novartis Pharmaceuticals Corporation: Consulting Fee  
PharmaEssentia Corporation: Consulting Fee  
Promedior, Inc.: Consulting Fee  
Sierra Oncology: Consulting Fee

**Mark B. Geyer, MD**

Actinium Pharmaceuticals, Inc.: Grant/Research Support  
Allogene Therapeutics: Consulting Fee  
Amgen Inc.: Grant/Research Support  
sanofi-aventis U.S.: Consulting Fee; Grant/Research Support



**Faculty Disclosures (continued)**

***Presenting Faculty***

The faculty listed below have the following **relevant** financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

**Jason Gotlib, MD, MS**

AbbVie, Inc.: Grant/Research Support; Honoraria  
Blueprint Medicines: Grant/Research Support; Honoraria  
Bristol-Myers Squibb Company: Grant/Research Support  
Cogent Biosciences: Grant/Research Support; Honoraria  
Deciphera Pharmaceuticals, Inc.: Grant/Research Support  
Imago Biosciences: Honoraria  
Incyte Corporation: Grant/Research Support; Honoraria  
Kartos: Grant/Research Support; Honoraria  
Novartis Pharmaceuticals Corporation: Honoraria  
PharmaEssentia: Honoraria  
Protagonist Therapeutics: Grant/Research Support; Honoraria

**Brian T. Hill, MD, PhD**

AbbVie, Inc.: Consulting Fee  
AstraZeneca Pharmaceuticals LP: Consulting Fee  
BeiGene: Consulting Fee  
Genentech, Inc.: Consulting Fee

**Marshall S. Horwitz, MD, PhD**

AbbVie, Inc.: Equity Interest/Stock Options  
Biogen Idec: Equity Interest/Stock Options  
Gilead Sciences, Inc.: Equity Interest/Stock Options  
Regeneron Pharmaceuticals, Inc.: Equity Interest/Stock Options

**Mark R. Litzow, MD**

AbbVie, Inc.: Grant/Research Support  
Actinium Pharmaceuticals, Inc.: Grant/Research Support  
Amgen Inc.: Grant/Research Support  
Astellas Pharma US, Inc.: Grant/Research Support  
BioSight Ltd.: Scientific Advisor  
Jazz Pharmaceuticals Inc.: Scientific Advisor  
Novartis Pharmaceuticals Corporation: Grant/Research Support  
Pluristem Therapeutics Inc.: Grant/Research Support  
Syndax Pharmaceuticals Inc.: Grant/Research Support



**Faculty Disclosures (continued)**

***Presenting Faculty***

The faculty listed below have the following **relevant** financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

**Aaron C. Logan, MD, PhD**

AbbVie, Inc.: Consulting Fee  
Agiros, Inc.: Consulting Fee  
Amgen Inc.: Consulting Fee; Grant/Research Support  
Astellas Pharma US, Inc.: Grant/Research Support  
Autolus Therapeutics: Grant/Research Support  
Bristol-Myers Squibb Company: Consulting Fee  
Jazz Pharmaceuticals Inc.: Grant/Research Support  
Kadmon Corporation: Grant/Research Support  
Kite Pharma: Grant/Research Support  
Pfizer Inc.: Consulting Fee  
Pharmacyclics: Grant/Research Support

**Patricia A. Mangan, RN, MSN, APRN-BC**

Amgen Inc.: Honoraria  
Bristol-Myers Squibb Company: Honoraria  
Celgene Corporation: Honoraria  
GlaxoSmithKline: Honoraria  
Janssen Pharmaceutica Products, LP: Honoraria  
Karyopharm Therapeutics: Honoraria  
Novartis Pharmaceuticals Corporation: Consulting Fee  
sanofi-aventis U.S.: Honoraria  
Takeda Pharmaceuticals North America, Inc.: Honoraria

**Anthony Mato, MD, MSCE**

AbbVie, Inc.: Grant/Research Support; Scientific Advisor  
Acerta Pharma: Grant/Research Support; Scientific Advisor  
Adaptive Biotechnologies: Grant/Research Support; Scientific Advisor  
Celgene Corporation: Scientific Advisor  
Johnson & Johnson: Grant/Research Support; Scientific Advisor  
Loxo Oncology, Inc.: Grant/Research Support  
Pharmacyclics: Grant/Research Support; Scientific Advisor  
Sunesis Pharmaceuticals, Inc.: Grant/Research Support; Scientific Advisor  
TG Therapeutics, Inc.: Grant/Research Support; Scientific Advisor  
Verastem, Inc.: Scientific Advisor  
Zhejiang DTRM Biopharma Co. Ltd.: Grant/Research Support; Scientific Advisor



**Faculty Disclosures (continued)**

***Presenting Faculty***

The faculty listed below have the following **relevant** financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

**Tycel Phillips, MD**

AbbVie, Inc.: Consulting Fee; Grant/Research Support; Scientific Advisor  
AstraZeneca Pharmaceuticals LP: Consulting Fee  
Bayer HealthCare: Consulting Fee; Grant/Research Support  
BeiGene: Consulting Fee  
Bristol-Myers Squibb Company: Consulting Fee; Grant/Research Support  
Eli Lilly and Company: Consulting Fee  
Genentech, Inc.: Consulting Fee; Grant/Research Support; Scientific Advisor  
Incyte Corporation: Consulting Fee; Grant/Research Support  
Kite Pharma: Consulting Fee  
MorphoSys AG: Consulting Fee  
Pharmacyclics: Consulting Fee  
Seattle Genetics, Inc.: Consulting Fee; Scientific Advisor

**Daniel A. Pollyea, MD, MS**

AbbVie, Inc.: Grant/Research Support; Scientific Advisor  
Aprea Therapeutics: Scientific Advisor  
Arcellx: Scientific Advisor  
Astellas Pharma US, Inc.: Scientific Advisor  
AstraZeneca Pharmaceuticals LP: Scientific Advisor  
BeiGene: Scientific Advisor  
BerGenBio ASA: Scientific Advisor  
Bristol-Myers Squibb Company: Grant/Research Support; Scientific Advisor  
Celgene Corporation: Scientific Advisor  
Foghorn Therapeutics: Scientific Advisor  
Genentech, Inc.: Scientific Advisor  
Gilead Sciences, Inc.: Scientific Advisor  
GlycoMimetics, Inc.: Scientific Advisor  
HiberCell Inc.: Scientific Advisor  
ImmunoGen, Inc.: Scientific Advisor  
Jazz Pharmaceuticals Inc.: Scientific Advisor  
Karyopharm Therapeutics: Grant/Research Support; Scientific Advisor  
Kiadis Pharma: Scientific Advisor  
Kura Oncology, Inc.: Scientific Advisor  
Magenta Therapeutics: Scientific Advisor  
Medivir AB: Scientific Advisor  
Novartis Pharmaceuticals Corporation: Scientific Advisor  
Qihan Biotech: Scientific Advisor  
Ryvu Therapeutics: Scientific Advisor  
Syndax Pharmaceuticals Inc.: Scientific Advisor  
Syros Pharmaceuticals: Scientific Advisor  
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor  
Teva Pharmaceutical Industries Ltd: Grant/Research Support  
Zentalis Pharmaceuticals: Scientific Advisor



**Faculty Disclosures (continued)**

***Presenting Faculty***

The faculty listed below have the following **relevant** financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

**Noopur S. Raje, MD**

AbbVie, Inc.: Consulting Fee  
Amgen Inc.: Consulting Fee  
bluebird bio, Inc.: Grant/Research Support  
Bristol-Myers Squibb Company: Consulting Fee  
Caribou Biosciences, Inc.: Scientific Advisor  
Immuneel Therapeutics: Scientific Advisor  
Janssen Pharmaceutica Products, LP: Consulting Fee  
Pfizer Inc.: Consulting Fee  
sanofi-aventis U.S.: Consulting Fee  
Takeda Pharmaceuticals North America, Inc.: Consulting Fee

**Stephany Rodriguez, RN, MS, NP**

Genentech, Inc.: Product/Speakers Bureau

**Mazyar Shadman, MD, MPH**

AbbVie, Inc.: Consulting Fee; Grant/Research Support  
Adaptimmune Therapeutics plc: Consulting Fee  
Adaptive Biotechnologies: Consulting Fee  
AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research Support  
Atara Biotherapeutics: Consulting Fee; Grant/Research Support  
BeiGene: Consulting Fee; Grant/Research Support  
Bristol-Myers Squibb Company: Consulting Fee; Grant/Research Support  
Celgene Corporation: Grant/Research Support  
Eli Lilly and Company: Consulting Fee  
Epizyme: Consulting Fee  
Genentech, Inc.: Consulting Fee; Grant/Research Support  
Genmab A/S: Grant/Research Support  
Gilead Sciences, Inc.: Grant/Research Support  
Innate Pharma, Inc.: Consulting Fee  
Kite Pharma: Consulting Fee  
MEI Pharma Inc.: Consulting Fee  
Merck & Co., Inc.: Consulting Fee  
MorphoSys AG: Grant/Research Support  
Mustang Bio: Consulting Fee; Grant/Research Support  
Pharmacyclics: Consulting Fee; Grant/Research Support  
Regeneron Pharmaceuticals, Inc.: Consulting Fee  
Sound Biologics: Consulting Fee  
Sunesis Pharmaceuticals, Inc.: Grant/Research Support  
TG Therapeutics, Inc.: Consulting Fee; Grant/Research Support  
Vincerox Pharma: Grant/Research Support





**Faculty Disclosures (continued)**

***Presenting Faculty***

The faculty listed below have the following **relevant** financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

**Bijal Shah, MD**

Acrotech: Honoraria  
Adaptive Biotechnologies: Honoraria  
Amgen Inc.: Honoraria  
AstraZeneca Pharmaceuticals LP: Honoraria  
Autolus: Honoraria  
BeiGene: Honoraria  
Bristol-Myers Squibb Company/Celgene Corporation: Honoraria  
Jazz Pharmaceuticals Inc: Grant/Research Support  
Kite Pharma/Gilead Sciences, Inc.: Grant/Research Support; Honoraria  
Novartis Pharmaceuticals Corporation: Honoraria  
Pfizer Inc.: Honoraria  
Pharmacyclics: Honoraria  
Precision Biosciences, Inc: Honoraria  
Servier: Grant/Research Support

**Nicholas J. Short, MD**

Amgen Inc.: Consulting Fee; Honoraria  
Astellas Pharma US, Inc.: Grant/Research Support; Honoraria  
Novartis Pharmaceuticals Corporation: Consulting Fee  
Pfizer Inc.: Consulting Fee  
Stemline Therapeutics, Inc.: Grant/Research Support  
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support  
Xencor: Grant/Research Support

**David J. Straus, MD**

Seagen Inc.: Grant/Research Support  
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support

**Kendra L. Sweet, MD, MS**

Astellas Pharma US, Inc.: Consulting Fee  
BerGen Bio: Consulting Fee  
Curis: Consulting Fee  
Bristol-Myers Squibb Company: Consulting Fee; Scientific Advisor  
Gilead Sciences, Inc.: Consulting Fee; Scientific Advisor  
Incyte Corporation: Grant/Research Support  
Mayblytics: Consulting Fee  
Novartis Pharmaceuticals Corporation: Consulting Fee; Scientific Advisor

**Jennifer K. Tobin, PharmD, RPh**

Bristol-Myers Squibb Company: Scientific Advisor  
Curio Science: Scientific Advisor  
Karyopharm Therapeutics: Scientific Advisor  
Pharmacyclics: Scientific Advisor



**NCCN Staff Disclosures**

None of the other planners for this educational activity have **relevant** financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.